Abstract
Mammalian target of rapamycin inhibitors (mTOR-I), everolimus and sirolimus, are immunosuppressive drugs extensively used in renal transplantation. Their main mechanism of action is the inhibition of cell signaling through the PI3 K/Akt/mTOR pathway. This interesting mechanism of action confers to these medications both great immunosuppressive potential and important anti-neoplastic properties. Although the clinical utility of this drug category, as with other antineoplastic/immunosuppressants, is clear, the use of mTOR-I commonly results in the development of several complications. In particular, these agents may determine severe renal toxicity that, as recent studies report, seems clearly correlated to dose and duration of drug use. The mTOR-I-induced renal allograft spectrum of toxicity includes the enhanced incidence of delayed graft function, nephrotoxicity in particular when co-administered with calcineurin inhibitors (CNI) and onset of proteinuria. The latter effect appears highly frequent in patients undergoing mTOR-I treatment and significantly associated with a rapid graft lost. The damage leading to this complication interests both the glomerular and tubular area. mTOR-I cause an inhibition of proliferation in podocytes and the epithelial-to-mesenchymal transition in tubular cells. Interestingly, all these side effects are mostly reversible and dose related. Therefore, it is unquestionable that these particular drugs should be administered at the lowest dose able to maintain relatively low trough levels, in order to maximize their important and specific therapeutic effects while minimizing or avoiding drug toxicities. Utilization of low dosages of mTOR-I should be encouraged not only in CNI-combined schemas, but also when administered alone in a CNI-free immunosuppressive protocol.
Similar content being viewed by others
References
Cecka JM The UNOS renal transplant registry. Clin Transpl 2005:1–16
Starzl TE, Klintmalm GB, Weil R III et al (1981) Cyclosporin A and steroid therapy in sixty-six cadaver kidney recipients. Surg Gynecol Obstet 153:486–494
Wolfe RA, Roys EC, Merion RM (2010) Trends in organ donation and transplantation in the United States, 1999-2008. Am J Transplant 10(4 Pt 2):961–972
Geissler EK, Schlitt HJ, Thomas G (2008) mTOR, cancer, and transplantation. Am J Transplant 8:2212–2218
Chapman JR, Valantine H, Albanell J et al (2007) Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. Transplant Proc 39:2937–2950
Sehgal SN (1998) Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunnuosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 31:335–340
Kahan BD, For the Rapamune US Study Group (2000) Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicentre study. Lancet 356(9225):194–202
MacDonald AS, For the Rapamune Global Study Group (2001) A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 71(2):271–280
Groth CG, Backman L, Morales JM et al (1999) Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 67(7):1036–1042
Kreis H, Cisterne JM, Land W et al (2000) Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. The Sirolimus European Renal Transplant Study Group. Transplantation 69(7):1252–1260
Flechner SM, Glyda M, Cockfield S et al (2011) The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 11(8):1633–1644
Lorber MI, Mulgaonkar S, Butt KM (2005) Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 80(2):244–252
Ekberg H, Tedesco-Silva H, Demirbas A et al (2007) Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 375:2562–2575
Vitko S, Margreiter R, Weimar W et al (2005) Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 5(10):2521–2530
Ciancio G, Burke GW, Gaynor JJ et al (2004) A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 77:252–258
Larson TS, Dean PG, Stegall MD et al (2006) Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 6:514–522
Mendez R, Gonwa T, Yang HC, Weinstein S, Jensik S, Steinberg S, Prograf Study Group (2005) A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. Transplantation 80(3):303–309
Anil Kumar MS, Heifets M, Fyfe B, Saaed MI, Moritz MJ, Parikh MH, Kumar A (2005) Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsy. Transplantation 80(6):807–814
Gallon L, Perico N, Dimitrov BD, Winoto J, Remuzzi G, Leventhal J, Gaspari F, Kaufman D (2006) Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF. Am J Transplant 6(7):1617–1623
Flechner SM, Goldfarb D, Modlin C, Feng J, Krishnamurthi V, Mastroianni B, Savas K, Cook DJ, Novick AC (2002) Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 74:1070–1076
Watson CJ, Firth J, Williams PF et al (2005) A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant 5:2496–2503
Stallone G, Infante B, Schena A et al (2005) Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 16:3755–3762
Schena FP, Pascoe MD, Alberu J et al (2009) Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 87:233–242
Lebranchu Y, Thierry A, Toupance O et al (2009) Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant 9:1115–1123
Patel SJ, Dawson KL, Knight RJ et al (2011) The role of mTOR inhibition in renal transplant immune suppression. Dial Transplant 40:23–29
Penn I (1998) Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl 147–158
Kasiske BL, Snyder JJ, Gilbertson DT, Wang C (2004) Cancer after kidney transplantation in the United States. Am J Transplant 4(6):905–913
Vasudev B, Hariharan S (2007) Cancer after renal transplantation. Curr Opin Nephrol Hypertens 16(6):523–528
Buell JF, Gross TG, Woodle ES (2005) Malignancy after transplantation. Transplantation 80(2 Suppl):S254–S264
Dantal J, Pohanka E (2007) Malignancies in renal transplantation: an unmet medical need. Nephrol Dial Transplant 22(Suppl 1):i4–i10
Vajdic CM, MacDonald SP, McCredie MR et al (2006) Cancer incidence before and after kidney transplantation. JAMA 296(23):2823–2831
Villeneuve PJ, Schaubel DE, Fenton SS, Shepherd FA, Jiang Y, Mao Y (2007) Cancer incidence among Canadian kidney transplant recipients. Am J Transplant 7(4):941–948
Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M (2002) Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 73:1565–1572
Guba M, von Breitenbuch P, Steinbauer M et al (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8(2):128–135
Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD (2005) Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 80:883–889
Mathew T, Kreis H, Friend P (2004) Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 18:446–449
Campistol JM, Eris J, Oberbauer R et al (2006) Sirolimus therapy after early cyclosporine withdrawal reduces the risk of cancer in adult renal transplantation. J Am Soc Nephrol 17:581–589
Campistol JM, Gutierrez-Dalmau A, Torregrosa JV (2004) Conversion to sirolimus: a successful treatment for posttransplantation Kaposi’s sarcoma. Transplantation 77:760–762
Lebbe C, Euvrard S, Barrou B et al (2006) Sirolimus conversion for patients with posttransplant Kaposi’s sarcoma. Am J Transplant 6:2164–2168
Zmonarski SC, Boratyńska M, Rabczyński J, Kazimierczak K, Klinger M (2005) Regression of Kaposi’s sarcoma in renal graft recipients after conversion to sirolimus treatment. Transplant Proc 37(2):964–966
Stallone G, Schena A, Infante B et al (2005) Sirolimus for Kaposi’s sarcoma in renal transplant patients. N Engl J Med 352(13):1317–1323
Zaltzman JS, Prasad R, Chun K, Jothy S (2005) Resolution of renal allograft associated post-transplant lymphoproliferative disorder with introduction of sirolimus. Nephrol Dial Transplant 20(8):1748–1751
Mohsin N, Budrudden M, Kamble P et al (2007) Complete regression of cutaneous B cell lymphoma in a renal transplant patient after conversion from cyclosporine to sirolimus. Transplant Proc 39(4):1267–1271
Cullis B, D’Souza R, McCullagh P et al (2006) Sirolimus—induced remission of posttransplantation lymphoproliferative disorder. Am J Kidney Dis 47(5):e67–e72
Jiménez-Rivera C, Avitzur Y, Fecteau AH, Jones N, Grant D, Ng VL (2004) Sirolimus for pediatric liver transplant recipients with posttransplant lymphoproliferative disease and hepatoblastoma. Pediatr Transplant 8(3):243–248
Garcia VD, Bonamigo Filho JL, Neuman J et al (2003) Rituximab in association with rapamycin for posttransplant lymphoproliferative disease treatment. Transpl Int 16(3):202–206
Al-Akash SI, Al Makadma AS, Al Omari MG (2005) Rapid response to rituximab in a pediatric liver transplant recipient with posttransplant lymphoproliferative disease and maintenance with sirolimus monotherapy. Pediatr Transplant 9(2):249–253
Morales JM (2002) Influence of the new immunosuppressive combinations on arterial hypertension after renal transplantation. Kidney Int Suppl 82:S81–S87
Legendre C, Campistol JM, Squifflet JP et al (2003) Sirolimus European Renal Transplant Study Group: cardiovascular risk factors of sirolimus compared with cyclosporine: early experience from two randomized trials in renal transplantation. Transplant Proc 35(3 Suppl):151S–153S
Paoletti E, Marsano L, Bellino D, Cassottana P, Cannella G (2012) Effect of everolimus on left ventricular hypertrophy of de novo kidney transplant recipients: a 1 year, randomized, controlled trial. Transplantation 93:503–508
Joannidès R, Monteil C, de Ligny BH et al (2011) Immunosuppressant regimen based on sirolimus decreases aortic stiffness in renal transplant recipients in comparison to cyclosporine. Am J Transplant 11(11):2414–2422
Brattstrom C, Wilczek H, Tyden G et al (1998) Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation 65:1272–1274
Ekberg H, Bernasconi C, Nöldeke J et al (2010) Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrol Dial Transplant 25(6):2004–2010
Fortun J, Martin-Davila P, Pascual J et al (2010) Immunosuppressive therapy and infection after kidney transplantation. Transpl Infect Dis 12(5):397–405
Snyder JJ, Israni AK, Peng Y et al (2009) Rates of first infection following kidney transplant in the United States. Kidney Int 75(3):317–326
Nashan B, Gaston R, Emery V et al (2012) Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients. Transplantation 93(11):1075–1085
Araki K, Turner AP, Shaffer VO et al (2009) mTOR regulates memory CD8 T-cell differentiation. Nature 460:108–112
Benavides CA, Pollard VB, Mauiyyedi S, Podder H, Knight R, Kahan BD (2007) BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes. Transplantation 84:83–88
Zaza G, Tomei P, Ria P, Granata S, Boschiero L, Lupo A (2013) Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors. Clin Dev Immunol 2013:403280
Sánchez-Fructuoso AI, Ruiz JC, Pérez-Flores I et al (2010) Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus. Transplant Proc 42(8):3050–3052
Diekmann F, Andres A, Oppenheimer F (2012) mTOR inhibitor-associated proteinuria in kidney transplant recipients. Transplant Rev (Orlando) 26(1):27–29
Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM (2004) Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 4:1869–1875
Letavernier E, Pe’raldi MN, Pariente A, Morelon E, Legendre C (2005) Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 80(9):1198–1203
Morelon E, Kreis H (2003) Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. Transplant Proc 35(3 Suppl):52S–57S
Faul C, Donnelly M, Merscher-Gomez S et al (2008) The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 14(9):931–938
Saurina A, Campistol JM, Piera C et al (2006) Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria. Nephrol Dial Transplant 21(2):488–493
Coombes JD, Mreich E, Liddle C, Rangan GK (2005) Rapamycin worsens renal function and intratubular cast formation in protein overload nephropathy. Kidney Int 68(6):2599–2607
Inoki K, Mori H, Wang J et al (2011) mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest 121(6):2181–2196
Godel M, Hartleben B, Herbach N (2011) Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest 121(6):2197–2209
Gonwa T, Johnson C, Ahsan N (2003) Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation 75(12):2048–2053
Napoli KL, Wang ME, Stepkowski SM, Kahan BD (1998) Relative tissue distributions of cyclosporine and sirolimus after concomitant peroral administration to the rat: evidence for pharmacokinetic interactions. Ther Drug Monit 20(2):123–133
Podder H, Stepkowski SM, Napoli KL (2001) Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol 12(5):1059–1071
Anglicheau D, Pallet N, Rabant M (2006) Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. Kidney Int 70(6):1019–1025
Lo A, Egidi MF, Gaber LW et al (2004) Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation. Clin Transplant 18:53–61
Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF (2008) Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial. Transplantation 86:1187–1195
Hong JC, Kahan BD (2001) A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft function. Transplantation 71(9):1320–1328
McTaggart RA, Gottlieb D, Brooks J et al (2003) Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant 3(4):416–423
Lieberthal W, Fuhro R, Andry CC et al (2001) Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 281(4):F693–F706
Dantal J, Berthoux F, Moal MC et al (2010) Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. Transpl Int 23(11):1084–1093
Tryggvason K, Patrakka J, Wartiovaara J (2006) Hereditary proteinuria syndromes and mechanisms of proteinuria. N Engl J Med 354(13):1387–1401
Kwoh C, Shannon MB, Miner JH, Shaw A (2006) Pathogenesis of nonimmune glomerulopathies. Annu Rev Pathol 1:349–374
Pavenstadt H, Kriz W, Kretzler M (2003) Cell biology of the glomerular podocyte. Physiol Rev 83(1):253–307
Mundel P, Shankland SJ (2002) Podocyte biology and response to injury. J Am Soc Nephrol 13(12):3005–3015
Kerjaschki D (2001) Caught flat-footed: podocyte damage and the molecular bases of focal glomerulosclerosis. J Clin Invest 108(11):1583–1587
Benzing T (2004) Signaling at the slit diaphragm. J Am Soc Nephrol 15(6):1382–1391
Vollenbröker B, George B, Wolfgart M, Saleem MA, Pavenstädt H, Weide T (2009) mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes. Am J Physiol Renal Physiol 296(2):F418–F426
Müller-Krebs S, Weber L, Tsobaneli J et al (2013) Cellular effects of everolimus and sirolimus on podocytes. PLoS One 8(11):e80340
Stallone G, Infante B, Pontrelli P et al (2011) Sirolimus and proteinuria in renal transplant patients: evidence for a dose-dependent effect on slit diaphragm-associated proteins. Transplantation 91(9):997–1004
Baas MC, Kers J, Florquin S et al (2013) Cyclosporine versus everolimus: effects on the glomerulus. Clin Transplant 27:535–540
Smith KD, Wrenshall LE, Nicosia RF et al (2003) Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. J Am Soc Nephrol 14:1037–1045
Fervenza FC, Fitzpatrick PM, Mertz J, For the Mayo Nephrology Collaborative Group et al (2004) Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrol Dial Transplant 19:1288–1292
Marx SO, Jayaraman T, Go LO, Marks AR (1995) Rapamycin–FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 76:412–417
Masola V, Zaza G, Granata S, Gambaro G, Onisto M, Lupo A (2013) Everolimus-induced epithelial to mesenchymal transition in immortalized human renal proximal tubular epithelial cells: key role of heparanase. J Transl Med 11(1):292
Kurdián M, Herrero-Fresneda I, Lloberas N et al (2012) Delayed mTOR inhibition with low dose of everolimus reduces TGFβ expression, attenuates proteinuria and renal damage in the renal mass reduction model. PLoS One 7(3):e32516
Geissler EK, Schlitt HJ (2011) mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression. Kidney Int 79(5):502–511
Pontrelli P, Rossini M, Infante B et al (2008) Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy. Transplantation 85(1):125–134
Breuleux M, Klopfenstein M, Stephan C et al (2009) Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3 K/mTOR inhibition. Mol Cancer Ther 8(4):742–753
Wan X, Harkavy B, Shen N, Grohar P, Helman LJ (2007) Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 26(13):1932–1940
Bhaskar PT, Hay N (2007) The two TORCs and Akt. Dev Cell 12(4):487–502
Slomovitz BM, Coleman RL (2012) The PI3 K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res 18(21):5856–5864
Gilles C, Polette M, Mestdagt M et al (2003) Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res 63(10):2658–2664
Masola V, Gambaro G, Tibaldi E, Onisto M, Abaterusso C, Lupo A (2011) Regulation of heparanase by albumin and advanced glycation end products in proximal tubular cells. Biochim Biophys Acta 1813(8):1475–1482
Masola V, Onisto M, Zaza G, Lupo A, Gambaro G (2012) A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition. J Transl Med 10:213
Masola V, Maran C, Tassone E, Zin A, Rosolen A, Onisto M (2009) Heparanase activity in alveolar and embryonal rhabdomyosarcoma: implications for tumor invasion. BMC Cancer 9:304
Vlodavsky I, Friedmann Y (2001) Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 108(3):341–347
Nasser NJ (2008) Heparanase involvement in physiology and disease. Cell Mol Life Sci 65:1706–1715
Vreys V, David G (2007) Mammalian heparanase: what is the message? J Cell Mol Med 11:427–452
Szymczak M, Kuzniar J, Klinger M (2010) The role of heparanase in diseases of the glomeruli. Arch Immunol Ther Exp (Warsz) 58:45–56
Xu X, Wan X, Geng J, Li F, Yang T, Dai H (2013) Rapamycin regulates connective tissue growth factor expression of lung epithelial cells via phosphoinositide 3-kinase. Exp Biol Med (Maywood) 238(9):1082–1094
Nakagawa S, Masuda S, Nishihara K, Inui K (2010) mTOR inhibitor everolimus ameliorates progressive tubular dysfunction in chronic renal failure rats. Biochem Pharmacol 79(1):67–76
Lui SL, Chan KW, Tsang R, Yung S, Lai KN, Chan TM (2006) Effect of rapamycin on renal ischemia-reperfusion injury in mice. Transpl Int 19(10):834–839
Cicora F, Lausada N, Vasquez DN et al (2010) Sirolimus in kidney transplant donors and clinical and histologic improvement in recipients: rat model. Transplant Proc 42(1):365–370
Fuller TF, Freise CE, Serkova N, Niemann CU, Olson JL, Feng S (2003) Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion injury. Transplantation 76(11):1594–1599
Hebert LA, Agarwal G, Sedmak DD, Mahan JD, Becker W, Nagaraja HN (2000) Proximal tubular epithelial hyperplasia in patients with chronic glomerular proteinuria. Kidney Int 57(5):1962–1967
Morelon E, Stern M, Israel-Biet D, Kreis H et al (2001) Characteristics of sirolimus associated interstitial pneumonitis in renal transplant patient. Transplantation 72:787–790
Errasti P, Izquierdo D, Martín P et al (2010) Pneumonitis associated with mammalian target of rapamycin inhibitors in renal transplant recipients: a single-center experience. Transplant Proc 42(8):3053–3054
Rodríguez-Moreno A, Ridao N, García-Ledesma P et al (2009) Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center. Transplant Proc 41(6):2163–2165
Alexandru S, Ortiz A, Baldovi S et al (2008) Severe everolimus-associated pneumonitis in a renal transplant recipient. Nephrol Dial Transplant 23(10):3353–3355
Champion L, Stern M, Israël-Biet D et al (2006) Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med 144(7):505–509
Pham PT, Pham PC, Danovitch GM et al (2004) Sirolimus-associated pulmonary toxicity. Transplantation 77(8):1215–1220
Vandewiele B, Vandecasteele SJ, Vanwalleghem L, De Vriese AS (2010) Diffuse alveolar hemorrhage induced by everolimus. Chest 137(2):456–459
Vlahakis NE, Rickman OB, Morgenthaler T (2004) Sirolimus-associated diffuse alveolar hemorrhage. Mayo Clin Proc 79(4):541–545
Molas-Ferrer G, Soy-Muner D, Anglada-Martínez H et al (2013) Interstitial pneumonitis as an adverse reaction to mTOR inhibitors. Nefrologia 33(3):297–300
Kirby S, Satoskar A, Brodsky S et al (2012) Histological spectrum of pulmonary manifestations in kidney transplant recipients on sirolimus inclusive immunosuppressive regimens. Diagn Pathol 7:25
Augustine JJ, Knauss TC, Schulak JA et al (2004) Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant 4(12):2001–2006
Sofroniadou S, Goldsmith D (2011) Mammalian target of rapamycin (mTOR) inhibitors: potential uses and a review of haematological adverse effects. Drug Saf 34(2):97–115
Kahan BD, Podbielski J, Napoli KL et al (1998) Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 66:1040–1046
Thaunat O, Beaumont C, Chatenoud L et al (2005) Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state. Transplantation 80:1212–1219
Maiorano A, Stallone G, Schena A et al (2006) Sirolimus interferes with iron homeostasis in renal transplant recipients. Transplantation 82:908–912
Sánchez Fructuoso A, Calvo N, Moreno MA et al (2007) Study of anemia after late introduction of everolimus in the immunosuppressive treatment of renal transplant patients. Transplant Proc 39(7):2242–2244
Diekmann F, Rovira J, Diaz-Ricart M et al (2012) mTOR inhibition and erythropoiesis: microcytosis or anaemia? Nephrol Dial Transplant 27(2):537–541
Murgia MG, Jordan S, Kahan BD (1996) The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 49:209–216
Hong JC, Kahan BD (2007) Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation 69(10):2085–2090
Kovarik JM, Kaplan B, Tedesco Silva H et al (2002) Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation 73(6):920–925
Babinska A, Markell MS, Salifu MO et al (1998) Enhancement of human platelet aggregation and secretion induced by rapamycin. Nephrol Dial Transplant 13:3153–3159
Paul SR, Bennett F, Calvetti JA et al (1990) Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine. Proc Natl Acad Sci USA 87(19):7512–7516
Quesniaux VF, Wehrli S, Steiner C et al (1994) The immuno-suppressant rapamycin blocks in vitro responses to hematopoietic cytokines and inhibits recovering but not steady-state hematopoiesis in vivo. Blood 84:1543–1552
Kiberd BA (2002) Cardiovascular risk reduction in renal transplantation. Strategies for success. Minerva Urol Nefrol 54(2):51–63
Morrisett JD, Abdel-Fattah G, Hoogeveen et al (2002) Effects of Sirolimus on plasma lipid, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 43:1170–1180
Liu Q-Y, Nambi P (2004) Sirolimus upregulates aP2 expression in human monocytes and macrophages. Transplant Proc 36:3229–3231
Makowski L, Boord JB, Maeda K et al (2001) Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 7(6):699–705
Kasiske BL, de Mattos A, Flechner SM et al (2008) Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant 8(7):1384–1392
Romagnoli J, Citterio F, Nanni G et al (2006) Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine. Transplant Proc 38:1034–1036
Teutonico A, Schena PF, Di Paolo S (2005) Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 16:3128–3135
Sulanc E, Lane JT, Puumala SE et al (2005) New-onset diabetes after kidney transplantation: an application of 2003 International Guidelines. Transplantation 80:945–952
Syed NA, Khandelwal RL (2000) Reciprocal regulation of glycogen phosphorylase and glycogen synthase by insulin involving phosphatidylinositol-3 kinase and protein phosphatase-1 in HepG2 cells. Mol Cell Biochem 211:123–136
Lewis GF, Carpentier A, Adeli K, Giacca A (2002) Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 23:201–229
Mittelman SD, Bergman RN (2000) Inhibition of lipolysis causes suppression of endogenous glucose production independent of changes in insulin. Am J Physiol Endocrinol Metab 279:E630–E637
Bussiere CT, Lakey JR, Shapiro AM, Korbutt GS (2006) The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells. Diabetologia 49:2341–2349
Valente J, Hricik D, Weigel K et al (2003) Comparison of sirolimus versus mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am J Transplant 3(9):1128–1134
Dean PG, Lund WJ, Larson TS et al (2004) Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 77(10):1555–1561
Srivastava A, Muruganandham K, Vinodh PB et al (2010) Post-renal transplant surgical complications with newer immunosuppressive drugs: mycophenolate mofetil vs. m-TOR inhibitors. Int Urol Nephrol 42(2):279–284
Nair R, Huang X, Shorthouse R et al (1997) Antiproliferative effect of rapamycin on growth factor-stimulated human adult lung fibroblasts in vitro may explain its superior efficacy for prevention and treatment of allograft obliterative airway disease in vivo. Transplant Proc 29(1–2):614–615
Zaza G, Granata S, Sallustio F, Grandaliano G, Schena FP (2010) Pharmacogenomics: a new paradigm to personalize treatments in nephrology patients. Clin Exp Immunol 159(3):268–280
Conflict of interest
The authors have no conflicts of interest to disclosure.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zaza, G., Granata, S., Tomei, P. et al. mTOR inhibitors and renal allograft: Yin and Yang. J Nephrol 27, 495–506 (2014). https://doi.org/10.1007/s40620-014-0103-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40620-014-0103-y